AstraZeneca bolsters oncology portfolio with Daiichi Sankyo’s trastuzumab deruxtecan

AstraZeneca II
The agreement will see AstraZeneca and Daiichi Sankyo sharing global profits for the anticipated cancer-fighting blockbuster in all countries excluding Japan, where Daiichi Sankyo will retain exclusive rights.